• Lithium, Rab11a, and Exosomal Wnt10a in Osteogenesis

  2026-09-29

  Chen and colleagues show that lithium enhances bone mesenchymal stem cell osteogenesis by increasing Rab11a-associated trafficking and exosomal Wnt10a secretion, thereby activating Wnt/β-catenin signaling. The study also demonstrates that lithium-conditioned exosomes and GelMA hydrogel formulations improve osteogenic outcomes, providing a mechanistic framework for engineering extracellular vesicles for bone repair.

• GCRV104 Entry and Clathrin-Mediated Endocytosis

  2026-09-29

  Wang et al. used complementary pharmacological, ultrastructural, and molecular assays to show that genotype III grass carp reovirus enters CIK cells through a clathrin-mediated, dynamin-dependent, acidification-sensitive pathway. The study also found that Latrunculin B did not block viral entry under the tested conditions, providing a useful boundary for interpreting actin perturbation in endocytic and antiviral experiments.

• Rhodamine B: From Fluorescence to Drift Intelligence

  2026-09-28

  Rhodamine B is more than a familiar laboratory fluorophore. Its value extends from cell labeling and fluorescence microscopy to quantitative environmental tracing, creating a useful framework for translational researchers who need stronger controls across complex experimental systems. This article connects dye chemistry, assay design, and field validation while defining where the evidence is mature and where further validation is required.

• Tofacitinib: A Practical RA Macrophage Workflow

  2026-09-28

  Tofacitinib (CP-690550) offers a way to test how kinase inhibition reshapes GM-CSF-associated inflammation and mitochondrial phenotypes in rheumatoid arthritis macrophages. This guide turns recent human-sample and preclinical findings into an assay plan, with practical controls and troubleshooting for interpreting pathway and metabolic readouts.

• Polystyrene Nanoplastics Disrupt Placental Metabolism

  2026-09-27

  A 2026 study links gestational polystyrene nanoplastic exposure to placental NMNAT3 depletion, disturbed NAD+ metabolism, mitochondrial dysfunction, and ferritinophagy-associated ferroptosis. Its rescue experiments identify NMNAT3 and nicotinamide as potential points for further investigation, while leaving exposure parameters and human relevance important questions for follow-up.

• AO/PI Staining Solution for Cell Viability Workflows

  2026-09-26

  AO/PI Staining Solution separates membrane-intact cells from membrane-compromised cells, helping researchers count viable cells when debris or red blood cells can confound conventional methods. See how to incorporate this two-dye readout into diabetic nephropathy experiments without mistaking a viability measurement for evidence of apoptosis or pathway activity.

• Hepatocyte Arrb2 Limits Liver Ischemia–Reperfusion Injury

  2026-09-25

  This study identifies a hepatocyte Arrb2–6-ketoLCA pathway that favors M2 macrophage polarization and is associated with less hepatic ischemia–reperfusion injury. By combining transplant samples, a mouse liver-injury model, and cell-based experiments, it links hepatocyte signaling to immune-cell state and highlights a testable immunometabolic mechanism, while leaving clinical efficacy to be established.

• Tofacitinib Restores RA Macrophage Mitochondrial Function

  2026-09-25

  A 2026 study identifies GM-CSF-reprogrammed rheumatoid arthritis macrophages as an inflammatory state associated with oxidative stress and mitochondrial fragmentation. Across human RA specimens and preclinical models, Tofacitinib more broadly reversed this state than the tested metabolic interventions, alongside reduced GM-CSFRα expression and STAT5 signaling.

• Nigericin Workflows for pH and Ion-Flux Assays

  2026-09-24

  Use Nigericin to probe potassium/proton exchange, intracellular pH, and GSDMD-associated cell responses with workflows designed to separate ion-transport effects from downstream toxicity. The article also puts a bacterial antibiotic-metabolism study in context without implying that it tested Nigericin or established an antibiotic-adjuvant effect.

• Hepatocyte Arrb2 and 6-ketoLCA in Liver IRI

  2026-09-24

  A recent study links hepatocyte Arrb2 to increased 6-ketoLCA and M2-like macrophage polarization, identifying a metabolite-mediated route that may limit hepatic ischemia–reperfusion injury. Its combination of clinical samples, mouse injury modeling, cell experiments, and metabolite analysis provides a framework for investigating hepatocyte–macrophage communication, while leaving important questions about pathway details and clinical transferability open.

• FK866 (APO866): Mapping NAD+ Vulnerability

  2026-09-23

  Explore how FK866-mediated NAMPT inhibition connects NAD+ depletion, cancer-cell vulnerability, and biomarker-led translational research—from AML models to emerging PARP combination evidence in ovarian cancer.

• Fosinopril Clinical Pharmacokinetics and Clinical Potential

  2026-09-23

  The 1997 reference review explains how fosinopril, a phosphorus-containing ACE inhibitor prodrug, is converted to fosinoprilat and handled through both renal and biliary pathways. Its central clinical insight is that this disposition profile may reduce the impact of renal impairment on active-drug exposure while supporting blood pressure reduction, renal hemodynamics modulation, and cardiac remodeling assessment.

• Carvedilol Phosphate in Hepatic IRI Research

  2026-09-22

  A translational framework for using Carvedilol Phosphate to interrogate adrenergic signaling, Arrb2 biology, metabolite communication, and macrophage polarization in hepatic ischemia–reperfusion injury models.

• Arrb2–6-ketoLCA Signaling in Hepatic IRI

  2026-09-22

  The reference study identifies hepatocyte Arrb2 as a regulator of hepatic ischemia–reperfusion injury, linking parenchymal-cell signaling to 6-ketoLCA production and M2 macrophage polarization. Its combination of clinical samples, a hepatocyte-targeted mouse model, metabolomics, and hypoxia–reoxygenation experiments provides a mechanistic framework for studying hepatocyte–macrophage communication in liver transplantation research.

• CARM1 Peptide Inhibition in Breast Cancer

  2026-09-21

  The 2026 Pharmacological Research study introduces Pi-CARM1, a selective peptide inhibitor of the transcriptional coactivator and arginine methyltransferase CARM1, together with a TAT-linked version that enters breast cancer cells. The work connects CARM1 inhibition with suppression of tumor growth, altered estrogen receptor and interferon signaling, improved endocrine sensitivity, and synergistic responses to combination treatment.

8151 records 1/544 page Next 12345 下5页 Last page